Buchumschlag

Specific inhibitors of HIV capsid assembly binding to the c-terminal domain of the capsid protein: evaluation of 2-arylquinazolines as potential antiviral compounds

Assembly of human immunodeficiency virus (HIV-1) represents an attractive target for antiretroviral therapy which is not exploited by currently available drugs. We established high-throughput screening for assembly inhibitors based on competition of small molecules for the binding of a known dodecap...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Machara, Aleš (VerfasserIn) , Lux, Vanda (VerfasserIn) , Kožíšek, Milan (VerfasserIn) , Grantz Šašková, Klára (VerfasserIn) , Štěpánek, Ondřej (VerfasserIn) , Kotora, Martin (VerfasserIn) , Parkan, Kamil (VerfasserIn) , Pávová, Marcela (VerfasserIn) , Glass, Bärbel (VerfasserIn) , Sehr, Peter (VerfasserIn) , Lewis, Joe (VerfasserIn) , Müller, Barbara (VerfasserIn) , Kräusslich, Hans-Georg (VerfasserIn) , Konvalinka, Jan (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 2016
In: Journal of medicinal chemistry
Year: 2015, Jahrgang: 59, Heft: 2, Pages: 545-558
ISSN:1520-4804
DOI:10.1021/acs.jmedchem.5b01089
Online-Zugang:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1021/acs.jmedchem.5b01089
Volltext
Verfasserangaben:Aleš Machara, Vanda Lux, Milan Kožíšek, Klára Grantz Šašková, Ondřej Štěpánek, Martin Kotora, Kamil Parkan, Marcela Pávová, Bärbel Glass, Peter Sehr, Joe Lewis, Barbara Müller, Hans-Georg Kräusslich, and Jan Konvalinka
Beschreibung
Zusammenfassung:Assembly of human immunodeficiency virus (HIV-1) represents an attractive target for antiretroviral therapy which is not exploited by currently available drugs. We established high-throughput screening for assembly inhibitors based on competition of small molecules for the binding of a known dodecapeptide assembly inhibitor to the C-terminal domain of HIV-1 CA (capsid). Screening of >70000 compounds from different libraries identified 2-arylquinazolines as low micromolecular inhibitors of HIV-1 capsid assembly. We prepared focused libraries of modified 2-arylquinazolines and tested their capacity to bind HIV-1 CA to compete with the known peptide inhibitor and to prevent the replication of HIV-1 in tissue culture. Some of the compounds showed potent binding to the C-terminal domain of CA and were found to block viral replication at low micromolar concentrations.
Beschreibung:Publication date December 21, 2015
Gesehen am 22.05.2020
Beschreibung:Online Resource
ISSN:1520-4804
DOI:10.1021/acs.jmedchem.5b01089

Ähnliche Einträge